Currently, there are 257.00M common shares owned by the public and among those 256.33M shares have been available to trade.
The company’s stock has a 5-day price change of -10.62% and -6.69% over the past three months. VRTX shares are trading 11.75% year to date (YTD), with the 12-month market performance up to 12.46% higher. It has a 12-month low price of $377.85 and touched a high of $519.88 over the same period. VRTX has an average intraday trading volume of 1.48 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -8.08%, -8.48%, and -4.53% respectively.
Institutional ownership of Vertex Pharmaceuticals, Inc (NASDAQ: VRTX) shares accounts for 93.25% of the company’s 257.00M shares outstanding.
It has a market capitalization of $115.69B and a beta (3y monthly) value of 0.48. The earnings-per-share (ttm) stands at -$3.92. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.50% over the week and 3.50% over the month.
Earnings per share for the fiscal year are expected to increase by 4182.49%, and 16.36% over the next financial year.
Looking at the support for the VRTX, a number of firms have released research notes about the stock. Leerink Partners stated their Market Perform rating for the stock in a research note on May 06, 2025, with the firm’s price target at $503. Cantor Fitzgerald coverage for the Vertex Pharmaceuticals, Inc (VRTX) stock in a research note released on April 22, 2025 offered a Overweight rating with a price target of $535. Wells Fargo on their part issued Equal Weight rating on January 30, 2025.
